“Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials”, J of Skin, vol. 8, no. 4, p. s406, Jul. 2024, doi: 10.25251/skin.8.supp.406.